Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market
Market Insights on Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment covering sales outlook, demand forecast & up-to-date key trends
Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Drug Type, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market Snapshot (2023 to 2033)
The global Progressive Fibrosing Interstitial Lung Disease market is currently valued at US$ 4742.2 Million in 2023 and is anticipated to expand at a CAGR of 6.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 8654.1 Million by 2033.
The progressive fibrosing interstitial lung disease market is anticipated to increase due to factors such as increased awareness of PF-ILD along with the expected launch of emerging therapies during the forecast period (2023 to 2033).
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 4742.2 Million |
|
Projected Forecast Value (2033) |
US$ 8654.1 Million |
|
Global Growth Rate (2023 to 2033) |
6.2% CAGR |
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.
The type-specific segmentation majorly includes Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and ILDs.
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), are key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of the FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.
PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.
Let us know your requirement to get
100% FREE customization
Which are Some Prominent Drivers of the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?
Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth
Major factors driving the global progressive fibrosing interstitial lung disease treatment market are an increase in the incidence of lung infections, a surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.
Also, the increasing awareness regarding interstitial lung disease treatment among people, availability of cost-effective drugs in the market, and high prevalence of viral infection-causing lung disorder across the globe is expected to be the key factor driving the growth of progressive fibrosing interstitial lung disease treatment market.
The global progressive fibrosing interstitial lung disease treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.
The adoption of Inorganic Strategies by the Market Players is Expected to Drive Market Growth During the Forecast Period.
The increasing number of partnerships by key players is expected to boost the growth of the global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into a partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).
Which are the Trough Areas faced by the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?
High Expenditures Associated with Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Research and Development
Although the progressive fibrosing interstitial lung disease treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.
The high expense of therapies has severely hindered their widespread acceptance, particularly in underdeveloped nations. Such high treatment costs are also a subject of worry in developed nations, as many treatments may not be appropriately reimbursed, raising the patient's out-of-pocket expenditures dramatically.
Some side effects after the consumption of anti-inflammatory drugs will also hinder the growth of the progressive fibrosing interstitial lung disease market. All these factors are expected to derail the progress of the progressive fibrosing interstitial lung disease treatment market.
Many drugs have been withdrawn due to clinical challenges in later stages, implying that current emerging drugs may fail and clinical development failure weakens the emerging pipeline. This will disrupt progressive fibrosing interstitial lung disease treatment market growth.
Other factors such as a lack of sensitive clinical outcomes, suitable biomarkers, and difficulty in recruiting subjects, resulting in project delays or cancellations, are hindering the growth of the progressive fibrosing interstitial lung disease treatment market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystCountry-Wise Insights
What Makes USA an Attractive Market for Progressive Fibrosing Interstitial Lung Disease Treatment?
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 6.0% during the forecast period.
The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American interstitial lung disease treatment market in the years to come.
The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted for by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
Why Is Europe Emerging as an Opportunistic Progressive Fibrosing Interstitial Lung Disease Treatment Market?
Growing Prevalence of Lung-Related Disorders to Boost the Growth of the Market
Europe is expected to have the second maximum market share of the progressive fibrosing interstitial lung disease treatment market due to the high number of people suffering from COPD and asthma in the region.
Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
In addition, technologically advanced healthcare facilities are contributing to the growth of the market. Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, Europe is expected to possess a 56.7% market share in 2023.
Country-wise Forecast CAGRs for Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market
|
United Kingdom |
6.0% |
|
India |
5.6% |
|
South Korea |
5.7% |
|
China |
5.8% |
|
United States of America |
6.1% |
Category wise Insights
Based on Drug Type, Which Is the Most Prominent Segment in Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?
Corticosteroids Segment to Generate Significantly High Revenue
On the basis of drug type progressive fibrosing interstitial lung disease (PFILD) treatment market is classified into Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, and Others. Among these corticosteroids registers the highest demand in the progressive fibrosing interstitial lung disease treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. Corticosteroids, except nintedanib and pirfenidone, are commonly used as first-line therapies for ILDs other than IPF. Except for acute exacerbations, international guidelines for IPF treatment strongly recommend corticosteroid monotherapy.
The corticosteroids segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 5.9% over the forecast period 2022to2023.
By Distribution Channel, which segment generates high revenue in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment market?
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 65.5%. The growth of the segment is attributed to the increasing prevalence of Progressive Fibrosing Interstitial Lung Disease (PFILD) and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to Interstitial Lung Disease for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Start-up Scenario
How do New Entrants Contribute to the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the progressive fibrosing interstitial lung diseases treatment market.
Some of the start-ups in the progressive fibrosing interstitial lung diseases treatment market include-
- ILD Insights provides an information app to support the diagnosis and management of lung diseases. The app has features like information and resource materials for healthcare professionals and patient videos featuring opinion leaders, published studies, and clinical practice guidelines.
Competitive Landscape
Some of the key players present in the global progressive fibrosing interstitial lung diseases treatment markets are Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, GNI-EPS Pharmaceuticals, Inc. and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
- In February 2022, Boehringer Ingelheim announced that the USA Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis - irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
- FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, a fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.
- In March 2020 - Roche announced that the USA Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD
- In March 2021, F. Hoffmann-La Roche Ltd, a biotech company, announced that the USA Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the USA FDA for the treatment of the disease.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR 6.2% from 2023 to 2033 |
|
Expected Market Value (2023) |
US$4742.2 Million |
|
Projected Forecast Value (2033) |
US$ 8654.1 Million |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion & CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Covered in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market Industry Survey
Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Drug Type:
- Corticosteroids
- Immune Suppressing
- Anti-Fibrotic Medication
- Others
Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Route of Administration:
- Oral
- Injectable
Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market by Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
The global progressive fibrosing interstitial lung diseases treatment market is likely to reach a valuation of US$ 4742.2 million by the end of 2023.
Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics are some of the key players in the global progressive fibrosing interstitial lung diseases treatment market.
Sales of the progressive fibrosing interstitial lung diseases treatment market are likely to expand at 6.2% CAGR through 2033.
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the progressive fibrosing interstitial lung diseases treatment market.
By the end of 2033, the global market for progressive fibrosing interstitial lung diseases treatment market is predicted to reach a valuation of US$ 8654.1Million.
Table of Content
1. Executive Summary | Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Corticosteroids
5.3.2. Immune Suppressing
5.3.3. Anti-Fibrotic Medication
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Injectable
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Type
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Type
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Type
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Type
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Type
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Type
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Type
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Type
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Type
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Type
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channe
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Type
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Type
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Type
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Type
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Type
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Type
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Type
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Type
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Type
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Type
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Type
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Type
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Type
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Type
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Boehringer Ingelheim
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Bristol-Myers Squibb
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. FibroGen
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Hoffmann-La Roche Ltd
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Pliant Therapeutics, Inc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. United Therapeutics
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Vicore Pharma AB
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Avalyn Pharmaceuticals
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Beijing Continent Pharmaceutical
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. GNI-EPS Pharmaceuticals, Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018to 2033
Table 2: Global Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018to 2033
Table 6: North America Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 8: North America Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018to 2033
Table 10: Latin America Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 12: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018to 2033
Table 14: Europe Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 16: Europe Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 17: South Asia Value (US$ Million) Forecast by Country, 2018to 2033
Table 18: South Asia Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 19: South Asia Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 20: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 21: East Asia Value (US$ Million) Forecast by Country, 2018to 2033
Table 22: East Asia Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 23: East Asia Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 24: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 25: Oceania Value (US$ Million) Forecast by Country, 2018to 2033
Table 26: Oceania Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 27: Oceania Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 28: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Table 29: MEA Value (US$ Million) Forecast by Country, 2018to 2033
Table 30: MEA Value (US$ Million) Forecast by Drug Type, 2018to 2033
Table 31: MEA Value (US$ Million) Forecast by Route of Administration, 2018to 2033
Table 32: MEA Value (US$ Million) Forecast by Distribution Channel, 2018to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Value (US$ Million) by Drug Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 15: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Attractiveness by Drug Type, 2023 to 2033
Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Drug Type, 2023 to 2033
Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Attractiveness by Drug Type, 2023 to 2033
Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Drug Type, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Attractiveness by Drug Type, 2023 to 2033
Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Europe Value (US$ Million) by Drug Type, 2023 to 2033
Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Attractiveness by Drug Type, 2023 to 2033
Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Value (US$ Million) by Drug Type, 2023 to 2033
Figure 82: South Asia Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: South Asia Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Value (US$ Million) Analysis by Country, 2018to 2033
Figure 86: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 89: South Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 90: South Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 91: South Asia Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 92: South Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: South Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 95: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: South Asia Attractiveness by Drug Type, 2023 to 2033
Figure 98: South Asia Attractiveness by Route of Administration, 2023 to 2033
Figure 99: South Asia Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: South Asia Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Value (US$ Million) by Drug Type, 2023 to 2033
Figure 102: East Asia Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: East Asia Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Value (US$ Million) Analysis by Country, 2018to 2033
Figure 106: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 109: East Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 110: East Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 111: East Asia Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 112: East Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: East Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 115: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: East Asia Attractiveness by Drug Type, 2023 to 2033
Figure 118: East Asia Attractiveness by Route of Administration, 2023 to 2033
Figure 119: East Asia Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: East Asia Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Value (US$ Million) by Drug Type, 2023 to 2033
Figure 122: Oceania Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 123: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 124: Oceania Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Value (US$ Million) Analysis by Country, 2018to 2033
Figure 126: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 129: Oceania Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 130: Oceania Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 131: Oceania Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 132: Oceania Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 133: Oceania Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 134: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 135: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 136: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 137: Oceania Attractiveness by Drug Type, 2023 to 2033
Figure 138: Oceania Attractiveness by Route of Administration, 2023 to 2033
Figure 139: Oceania Attractiveness by Distribution Channel, 2023 to 2033
Figure 140: Oceania Attractiveness by Country, 2023 to 2033
Figure 141: MEA Value (US$ Million) by Drug Type, 2023 to 2033
Figure 142: MEA Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 143: MEA Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 144: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Value (US$ Million) Analysis by Country, 2018to 2033
Figure 146: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Value (US$ Million) Analysis by Drug Type, 2018to 2033
Figure 149: MEA Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 150: MEA Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 151: MEA Value (US$ Million) Analysis by Route of Administration, 2018to 2033
Figure 152: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 153: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 154: MEA Value (US$ Million) Analysis by Distribution Channel, 2018to 2033
Figure 155: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 156: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 157: MEA Attractiveness by Drug Type, 2023 to 2033
Figure 158: MEA Attractiveness by Route of Administration, 2023 to 2033
Figure 159: MEA Attractiveness by Distribution Channel, 2023 to 2033
Figure 160: MEA Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
